Glaucoma acceleration

Discussion in 'Alcon' started by Anonymous, Aug 7, 2014 at 3:14 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Is this for real? More fiasco thinking from upper management
     

  2. Anonymous

    Anonymous Guest

    What the heck is Alcon doing??? They have something shady up their sleeve
     
  3. Anonymous

    Anonymous Guest

    It makes more sense to me
     
  4. Anonymous

    Anonymous Guest

    Calling on pointless optometrists makes no sense they were not on our call list for a reason!
     
  5. Anonymous

    Anonymous Guest

    What makes more sense to you? Calling on ODs with a total 300 PGAs per year. Good luck
     
  6. Anonymous

    Anonymous Guest

    This was clearly a reactive decision to something more than low numbers. The managers didn't even know about it and they sat in a managers meeting days before.
     
  7. Anonymous

    Anonymous Guest

    A reaction to allergan?
     
  8. Anonymous

    Anonymous Guest

    I think they are piloting a new alignment to try and increase numbers to avoid a much larger layoff. Just my thoughts. I think someone got their butt chewed off the day before our call and made some very reactive decisions to try to blunt the inevitable.
     
  9. Anonymous

    Anonymous Guest

    What happened?
     
  10. Anonymous

    Anonymous Guest

    Alcon bozos management team is grasping for straws on the glaucoma side.
     
  11. Anonymous

    Anonymous Guest

    How about we stop worrying about travatan z and come up with the next big thing. Simbrinza is not the next big thing.
     
  12. Anonymous

    Anonymous Guest

    They should put the alphagan 0.1 in Simbrinza. The current alphagan is a shitty molecule.
     
  13. Anonymous

    Anonymous Guest

    It's still on patent. We don't own the molecule.
     
  14. Anonymous

    Anonymous Guest

    It's the same molecule moron, just a different formulation
     
  15. Anonymous

    Anonymous Guest

    It doesn't have the side effects as 0.2